Cagrilintide and GLP-1 combinations: hype vs. trial data

What did @callmekt1 actually say?

The creator is four weeks into retatrutide ("Retta") and reporting that appetite suppression appeared briefly after their Saturday injection but wore off in roughly ten hours. Frustrated, they added what sounds like cagrilintide ("the gag") at 0.5 mg and mentioned something called "C-Maxing" as a separate addition. Their core claim: "suppression my ass" — meaning retatrutide alone isn't cutting appetite enough at week four. They plan to report back on whether the stack changes anything.

To be clear about what we're dealing with: retatrutide is a triple agonist (GLP-1, GIP, and glucagon receptors) currently in Phase 3 trials. Cagrilintide is an amylin analog in late-stage development, often studied alongside semaglutide. Neither is FDA-approved. The creator is self-experimenting with research-grade compounds, stacking them without any stated medical supervision.

Does the science back this up?

The appetite suppression timeline complaint is actually consistent with what the pharmacokinetics literature shows, which gives this creator partial credit. Retatrutide has a half-life of roughly 6 days, meaning it takes several weeks to reach steady state. Expecting strong suppression at week four on a dose-escalation schedule is optimistic, not guaranteed.

The Phase 2 retatrutide trial (Jastreboff et al., 2023, NEJM) showed dose-dependent weight loss, but participants were titrated over months, not weeks. Suppression that "lasts 10 hours" is not how the drug is supposed to work mechanically. GLP-1 receptor agonists don't deliver a single daily suppression window. The sensation varies by individual, meal composition, and stress. Attributing a short suppression window entirely to the drug underperforming misreads how these compounds work physiologically.

On cagrilintide: the SCALE-CAGRI trial data (Enebo et al., 2021, The Lancet) showed amylin analogs do reduce caloric intake via slowed gastric emptying and satiety signaling, but again, this is a slow titration drug, not an immediate appetite kill switch.

What did they get wrong (or right)?

Right: the frustration is understandable and the short suppression window at week four is a real phenomenon some users experience during titration. That is not made up.

Wrong, and this matters: self-stacking retatrutide with cagrilintide and a third unnamed compound based on four weeks of subjective appetite experience is not how these drugs were studied. The REDEFINE Phase 3 trials for retatrutide use controlled titration over 16-24 weeks. Adding a second peptide because week four didn't feel impressive skips the part where the drug actually reaches therapeutic steady state.

The "C-Maxing" reference is vague enough to be unverifiable here, but if it refers to GHK-Cu (listed in the caption hashtags), that is a copper peptide with purported tissue-repair effects. There is no published evidence that GHK-Cu interacts with GLP-1 or amylin pathways, positively or negatively. Stacking unknowns onto an already unstudied combination is a risk the creator does not acknowledge.

What should you actually know?

Retatrutide is not approved for any use. Cagrilintide is not approved for any use. Combining them is not a studied protocol outside of controlled clinical settings. That does not mean everyone who does this will be harmed, but it does mean nobody actually knows the safety profile of this combination at any dose in an unsupervised outpatient setting.

The appetite experience the creator describes — variable suppression, eating past comfortable fullness — is documented in GLP-1 literature as common during titration (Rubino et al., 2022, NEJM). It typically resolves as dose escalates toward therapeutic range. Jumping to a stacked protocol before reaching that range means you may never know which compound, at what dose, was actually responsible for any outcome, good or bad.

If you are considering any of these compounds through a regulated telehealth provider, ask specifically about titration schedules, monitoring protocols, and what qualifies as a reason to stop. "I wasn't feeling suppressed at week four" is not, on its own, a clinical signal to add a second peptide.